Drugs / NXP900
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07315113 | Dec 2025 → Dec 2026 expected | lung cancer | Nuvectis Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05873686 | Oct 2023 → Mar 2027 expected | kidney cancer, lung adenocarcinoma, mesothelioma, non-small cell squamous lung carcinoma | Nuvectis Pharma, Inc. | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NXP900 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07315113 ↗ |
| Known as | DERIVATIVE 11A | ChEMBL registry synonym — accepted as the source's own label CHEMBL3824089 ↗ |
| Known as | ECF506 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3824089 ↗ |
| Action | Inhibit | “NXP900 is an orally administered SRC/YES1 kinase inhibitor” NCT05873686 ↗ |
| Modality | Small molecule | — CHEMBL3824089 ↗ |
| Route | Oral | “NXP900 is an orally administered SRC/YES1 kinase inhibitor” NCT05873686 ↗ |
| Target | SRC | “NXP900 is an orally administered SRC/YES1 kinase inhibitor” NCT05873686 ↗ |
| Target | YES1 | “NXP900 is an orally administered SRC/YES1 kinase inhibitor” NCT05873686 ↗ |